Compare AbbVie Inc (ABBV) vs EHang Holdings Ltd - ADR (EH) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

EHang Holdings trades at $5.52, down 12.52% over 24 hours, reflecting bearish technical signals and weak quarterly earnings. The company reported a net loss of $275.98 million for 2025 with a -77.56% net margin, though revenue reached $417.98 million. Recent news highlights volatility, including an 18% surge on June 15, 2026, following a Q1 2026 earnings miss reported by The Motley Fool on June 9, 2026.

The outlook remains challenged by persistent losses and high cash burn, but analyst consensus suggests moderate upside with a $7.75 price target. Key risks include execution delays in eVTOL commercialization and reliance on financing amid negative cash flows, while institutional sentiment is mixed with 40% buy ratings.